VSTMVerastem, Inc.
Price
-24%1YEnd-of-day closes, not the intraday tick.
Mostly good, one thing to check: safety
Quality strong, a flag to check, growing in the filings, the market with it.
Charts
As reported to the SEC, without any scoring.
Verastem, Inc. (VSTM) reported revenue of $40M in Q2 2026 (quarter ended Jun 30, 2026), up 1775% from the same quarter a year earlier. That came with net loss of $35M. For the full year FY2025, revenue was $31M (+209% year on year) and net income −$209M. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 7, 2026On August 6, 2026 (the “Amendment Closing Date”), Verastem, Inc., (the “Company”) entered into Amendment No. 3 (the “Amendment”) to that certain Note Purchase Agreement, dated as of January 13, 2025 (the “Original Closing Date”), as previously amended by Amendment No. 1 dated as of October 31, 2025 and Amendment No. 2 …Material agreement entered · Form 8-K
- Aug 6, 2026Verastem Oncology Reports Second Quarter 2026.Earnings release · press release
- Jun 23, 2026On June 23, 2026, the Company also (i) announced preliminary data from the ongoing TARGET-D 101 Phase 1/2 clinical trial evaluating VS-7375 in patients with advanced KRAS G12D-mutated solid tumors and provided an update on the status of expected key milestones in the development of VS-7375 and (ii) announced its …Regulation FD disclosure · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.